CN104144919B - 茶氨酸衍生物与羧酸香豆素衍生物的缩合产物及其中间体、其制备方法和用途 - Google Patents

茶氨酸衍生物与羧酸香豆素衍生物的缩合产物及其中间体、其制备方法和用途 Download PDF

Info

Publication number
CN104144919B
CN104144919B CN201380011625.1A CN201380011625A CN104144919B CN 104144919 B CN104144919 B CN 104144919B CN 201380011625 A CN201380011625 A CN 201380011625A CN 104144919 B CN104144919 B CN 104144919B
Authority
CN
China
Prior art keywords
compound
cancer
pharmaceutical composition
preparation
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380011625.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104144919A (zh
Inventor
张国营
刘昆
张颖
姚建文
关玉昆
吴犇昊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhang Guoying
Original Assignee
Shandong Dong Ying Ying Hao Biological Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201210363369.XA external-priority patent/CN103690530A/zh
Priority claimed from CN201210363378.9A external-priority patent/CN103690531A/zh
Priority claimed from CN201210363366.6A external-priority patent/CN103690528A/zh
Priority claimed from CN201210363367.0A external-priority patent/CN103690529A/zh
Priority claimed from CN201210515827.7A external-priority patent/CN103845325A/zh
Priority claimed from CN201210515826.2A external-priority patent/CN103845324A/zh
Priority claimed from CN 201310030234 external-priority patent/CN103110621A/zh
Priority to CN201380011625.1A priority Critical patent/CN104144919B/zh
Application filed by Shandong Dong Ying Ying Hao Biological Technology Co Ltd filed Critical Shandong Dong Ying Ying Hao Biological Technology Co Ltd
Publication of CN104144919A publication Critical patent/CN104144919A/zh
Publication of CN104144919B publication Critical patent/CN104144919B/zh
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201380011625.1A 2012-09-27 2013-09-25 茶氨酸衍生物与羧酸香豆素衍生物的缩合产物及其中间体、其制备方法和用途 Active CN104144919B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201380011625.1A CN104144919B (zh) 2012-09-27 2013-09-25 茶氨酸衍生物与羧酸香豆素衍生物的缩合产物及其中间体、其制备方法和用途

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
CN201210363369X 2012-09-27
CN201210363369.X 2012-09-27
CN201210363378.9 2012-09-27
CN2012103633789 2012-09-27
CN201210363366.6 2012-09-27
CN201210363367.0 2012-09-27
CN2012103633670 2012-09-27
CN201210363369.XA CN103690530A (zh) 2012-09-27 2012-09-27 茶氨酸氯香酰胺等在制备具有预防和治疗癌症等疾病的产品中的应用
CN2012103633666 2012-09-27
CN201210363367.0A CN103690529A (zh) 2012-09-27 2012-09-27 茶甲香酸等在制备具有预防和治疗癌症等疾病的产品中的应用
CN201210363366.6A CN103690528A (zh) 2012-09-27 2012-09-27 茶氨酸溴香酰胺在制备具有预防和治疗癌症等疾病的产品中的应用
CN201210363378.9A CN103690531A (zh) 2012-09-27 2012-09-27 茶乙香酸等在制备具有预防和治疗癌症等疾病的产品中的应用
CN201210515827.7A CN103845325A (zh) 2012-12-06 2012-12-06 茶氨酸硝香酰胺在制备具有预防和治疗癌症等疾病的产品中的应用
CN2012105158277 2012-12-06
CN2012105158262 2012-12-06
CN201210515826.2A CN103845324A (zh) 2012-12-06 2012-12-06 茶氨酸氟香酰胺在制备具有预防和治疗癌症等疾病的产品中的应用
CN201210515827.7 2012-12-06
CN201210515826.2 2012-12-06
CN2013100302346 2013-01-28
CN201310030234.6 2013-01-28
CN 201310030234 CN103110621A (zh) 2013-01-28 2013-01-28 茶双氯香酰胺和茶双溴香酰胺等在制备具有预防和治疗癌症等疾病的产品中的应用
PCT/CN2013/084146 WO2014048313A1 (zh) 2012-09-27 2013-09-25 茶氨酸衍生物与羧酸香豆素衍生物的缩合产物及其中间体、其制备方法和用途
CN201380011625.1A CN104144919B (zh) 2012-09-27 2013-09-25 茶氨酸衍生物与羧酸香豆素衍生物的缩合产物及其中间体、其制备方法和用途

Publications (2)

Publication Number Publication Date
CN104144919A CN104144919A (zh) 2014-11-12
CN104144919B true CN104144919B (zh) 2018-07-03

Family

ID=50386997

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380011625.1A Active CN104144919B (zh) 2012-09-27 2013-09-25 茶氨酸衍生物与羧酸香豆素衍生物的缩合产物及其中间体、其制备方法和用途

Country Status (5)

Country Link
US (1) US9518038B2 (enExample)
EP (1) EP2902388B1 (enExample)
JP (1) JP6404220B2 (enExample)
CN (1) CN104144919B (enExample)
WO (1) WO2014048313A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108069929B (zh) * 2016-11-18 2021-06-15 中国科学院大连化学物理研究所 3-取代香豆素类衍生物及应用和gpr35受体的激动剂
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
EP4081209A4 (en) * 2019-12-24 2024-04-24 The Regents of the University of California Compositions and methods for treating cancer and improving epithelial homeostasis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317774A (en) * 1978-03-24 1982-03-02 American Cyanamid Company 6-[D-α-(Coumarin-3-carboxamido)arylacetamido]-penicillanic acids or salts
CN101484430A (zh) * 2006-07-04 2009-07-15 荷兰联合利华有限公司 茶氨酸衍生物、其用途及其制备方法
WO2009089508A1 (en) * 2008-01-11 2009-07-16 The Regents Of The University Of California Activators of executioner procaspases 3, 6 and 7
CN103110621A (zh) * 2013-01-28 2013-05-22 烟台大学 茶双氯香酰胺和茶双溴香酰胺等在制备具有预防和治疗癌症等疾病的产品中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008059578A1 (de) * 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317774A (en) * 1978-03-24 1982-03-02 American Cyanamid Company 6-[D-α-(Coumarin-3-carboxamido)arylacetamido]-penicillanic acids or salts
CN101484430A (zh) * 2006-07-04 2009-07-15 荷兰联合利华有限公司 茶氨酸衍生物、其用途及其制备方法
WO2009089508A1 (en) * 2008-01-11 2009-07-16 The Regents Of The University Of California Activators of executioner procaspases 3, 6 and 7
CN103110621A (zh) * 2013-01-28 2013-05-22 烟台大学 茶双氯香酰胺和茶双溴香酰胺等在制备具有预防和治疗癌症等疾病的产品中的应用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Bhumika Thati et al..In vitro anti-tumour and cyto-selective effects of coumarin-3-carboxylic acid and three of its hydroxylated derivatives, along with their silver-based complexes, using human epithelial carcinoma cell lines.《Cancer Letters》.2006,第248卷(第2期),第321-331页. *
Coumarin-3-carboxylic acid derivatives as potentiators and inhibitors of recombinant and native N-methyl-D-aspartate receptors;Mark W. Irvine et al.;《Neurochemistry International》;20120113;第61卷(第4期);第593-600页 *
L-Theanine: properties, synthesis and isolation from tea;Quan V Vuong et al.;《J Sci Food Agric》;20110329;第91卷;第1931-1939页 *
Solid Phase Synthesis of Substituted Coumarin-3-Carboxylic Acids via the Knoevenagel Condensation;Brett T. Watson et al.;《Tetrahedron Letters》;19980908;第39卷(第13期);第6087-6090页 *
Synthesis and selective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin derivatives;Daniela Secci et al.;《European Journal of Medicinal Chemistry》;20110719;第46卷;第4846-4852页 *
简单香豆素药理作用与构效关系研究进展;吴龙火等;《医药导报》;20100401;第29卷(第4期);第498-501页 *
香豆素类化合物抗肿瘤作用研究进展;郝光等;《中国中药杂志》;20080915;第33卷(第18期);第2016-2019页 *

Also Published As

Publication number Publication date
WO2014048313A1 (zh) 2014-04-03
US9518038B2 (en) 2016-12-13
CN104144919A (zh) 2014-11-12
EP2902388B1 (en) 2019-03-13
EP2902388A1 (en) 2015-08-05
US20150239861A1 (en) 2015-08-27
JP6404220B2 (ja) 2018-10-10
EP2902388A4 (en) 2016-08-31
JP2016500649A (ja) 2016-01-14

Similar Documents

Publication Publication Date Title
CN102212008B (zh) 丹参素川芎嗪衍生物及其制备方法和应用
US10765660B2 (en) Agent containing flavonoid derivatives for treating cancer and inflammation
CN105111271B (zh) 一种熊果酸-阿司匹林偶联物及其在制备预防肿瘤转移药物中的应用
RU2557235C1 (ru) Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты
CN103739616B (zh) 含噻唑基雷帕霉素类衍生物及其应用
CN108440583A (zh) 一种新的硼酸衍生物及其药物组合物
CN103275051B (zh) 一种7,3’,4’-三羟基黄酮衍生物及其在制备治疗肝癌药物中的应用
CN104144919B (zh) 茶氨酸衍生物与羧酸香豆素衍生物的缩合产物及其中间体、其制备方法和用途
EP3252039B1 (en) Compound containing indoleacetic acid core structure and use thereof
CN103690528A (zh) 茶氨酸溴香酰胺在制备具有预防和治疗癌症等疾病的产品中的应用
CN102827142B (zh) 一类喹啉-8-甲酰胺类化合物、其制备方法及其医药用途
CN103110621A (zh) 茶双氯香酰胺和茶双溴香酰胺等在制备具有预防和治疗癌症等疾病的产品中的应用
CN103845325A (zh) 茶氨酸硝香酰胺在制备具有预防和治疗癌症等疾病的产品中的应用
Li et al. Synthesis, biological activity evaluation and mechanism of action of novel bis-isatin derivatives as potential anti-liver cancer agents
CN103690531A (zh) 茶乙香酸等在制备具有预防和治疗癌症等疾病的产品中的应用
CN115043878B (zh) 具有肿瘤靶向的生物素化金（i）配合物及其制备方法和应用
CN101898985A (zh) Bcl-2蛋白的N-取代苯磺酰基-取代苯甲酰胺类小分子抑制剂及其应用
CN103690530A (zh) 茶氨酸氯香酰胺等在制备具有预防和治疗癌症等疾病的产品中的应用
CN103130774A (zh) 具有酪氨酸激酶抑制作用的化合物及其制备方法和应用
CN103845324A (zh) 茶氨酸氟香酰胺在制备具有预防和治疗癌症等疾病的产品中的应用
CN110734429B (zh) 松萝烟酰胺化合物及其制备方法与应用
CN103690529A (zh) 茶甲香酸等在制备具有预防和治疗癌症等疾病的产品中的应用
CN101684115B (zh) 4-(5-((2-(4-吗啉基-6-苯氨基-1,3,5-三嗪-2-基)亚肼基)甲基)呋喃-2-基)苯甲酸、其制备方法及用途
CN102603635B (zh) 格尔德霉素衍生物及其制备方法和用途
CN109824641A (zh) 一种具有抗癌活性的白杨素异亮氨酸衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SHANDONG YINGDONG YINGHAO BIOTECHNOLOGY CO., LTD.

Free format text: FORMER OWNER: WUWEI MARINE BIOTECHNOLOGY CO., LTD.

Effective date: 20141212

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 238300 WUHU, ANHUI PROVINCE TO: 264670 YANTAI, SHANDONG PROVINCE

TA01 Transfer of patent application right

Effective date of registration: 20141212

Address after: 264670 101 Aerospace Road, hi tech Zone, Shandong, Yantai

Applicant after: Shandong Yingdong Yinghao Biotechnology, Inc.

Address before: 238300 Xu Dong Road, Wuhu, Anhui, Wuwei County

Applicant before: Wuwei County Marine Biotechnology Co.,Ltd.

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240813

Address after: 1-1202, Building G2, Yantai University, No. 30 Qingquan Road, Laishan District, Yantai City, Shandong Province, China 264000

Patentee after: Zhang Guoying

Country or region after: China

Address before: 264670 No. 101, Hangtian Road, high tech Zone, Yantai City, Shandong Province

Patentee before: Shandong Yingdong Yinghao Biotechnology, Inc.

Country or region before: China